Meeting
2015 Genitourinary Cancers Symposium
Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma.
Authors
Shiven B. Patel
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Shiven B. Patel , Neeraj Agarwal , JoAnn Hsu , Srinivas Kiran Tantravahi , David Gill , Winston Vuong , Julia A. Batten , David D. Stenehjem , Sumanta Kumar Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 460)
DOI
10.1200/jco.2015.33.7_suppl.460
Abstract #
460
Poster Bd #
E18
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma.
First Author: Shiven B. Patel
Poster
2020 ASCO Virtual Scientific Program
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
First Author: Shaan Dudani
Poster
2020 Genitourinary Cancers Symposium
Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
First Author: Igor Stukalin
Poster
2018 ASCO Annual Meeting
Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.
First Author: Martin Boegemann